纳米药物研发的实践与思考

中国医药导刊 ›› 2022, Vol. 24 ›› Issue (4): 305-313.

纳米药物研发的实践与思考

王祉琪1，2，黄元政3，朱丹丹3，刘潇璇3*，梁兴杰1，4*

1.国家纳米科学中心，中国科学院纳米科学卓越创新中心，中国科学院纳米生物效应与安全性重点实验室，北京 100190； 2.大连医科大学附属第一医院麻醉科，辽宁大连 116011; 3.中国药科大学天然药物活性组分与药效国家重点实验室，药物科学研究院高端药物制剂与材料研究中心，江苏南京 210009； 4. 中国科学院大学，北京 100049

收稿日期:2022-06-09 出版日期:2022-04-28 发布日期:2022-04-28
基金资助:
国家重点研究开发计划（项目编号：2021YFA1201000；项目名称：基于双亲性可离子化高分子组装体的抗病毒纳米药物研究）；中华人民共和国科学技术部，国家重点研发计划“政府间国际科技创新合作/港澳台科技创新合作”重点专项项目（项目编号：2018YFE0117800；项目名称：纳米健康医疗技术的生命周期中的安全性研究）；国家自然科学基金重点项目（项目编号：32030060）；国家自然科学基金国际合作重点项目（项目编号：51861135103）；“京津冀基础研究合作项目”（项目编号：19JCZDJC64100）

Exploration and Considerations on the Development of Nanomedicine

1.CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety， CAS Center for Excellence in Nanoscience， National Center for Nanoscience and Technology of China， Beijing 100190，China; 2.Department of Anesthesiology， the First Affiliated Hospital of Dalian Medical University， Liaoning Dalian 116011，China;3.State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases，Center of Advanced Pharmaceuticals and Biomaterials， China Pharmaceutical University， Jiangsu Nanjing 210009，China; 4.University of Chinese Academy of Sciences, Beijing 100049，China；

Received:2022-06-09 Online:2022-04-28 Published:2022-04-28

摘要/Abstract

摘要： 随着纳米技术的不断发展，纳米药物因其靶向、高效、低毒等特性，被广泛应用于各种重大恶性疾病的治疗，并成为当下研究热点。然而，伴随着纳米药物逐步进入临床或临床前研究，对其所涉及的纳米材料的生物安全性的关注也日渐增加。当前，国内外对于纳米材料的有效性和安全性评价方式尚未达成共识，仍缺乏一个科学和系统的评估体系。鉴于此，“欧盟地平线2020 - SAFE-N-MEDTECH”项目针对当前几个主要的纳米医学研究方向，联合世界各地（欧洲、南美洲和中国）涉及纳米健康医疗领域的相关人员，共同参与研究，期望建立一个较为完善的纳米健康医疗技术的开放式测试平台，以推动纳米产业的全球化发展。该国际合作项目涉及纳米健康医疗技术的多个领域，如纳米药物和纳米医疗器械等，本课题组依托此国际合作项目开展了针对肿瘤和骨相关疾病的创新纳米药物研发。本研究拟以肿瘤和骨相关疾病的创新纳米药物研发为例，简要阐述纳米药物的优势和特点，以及基于疾病特征的纳米药物研发的方法和思路，以期能给予纳米医疗领域从业人员一定借鉴和帮助。

关键词: font-size:medium, ">纳米药物；纳米技术；恶性肿瘤；类风湿性关节炎；“欧盟地平线2020”项目

Abstract: With the continuous development of nanotechnology， nanomedicines are emerging as promising therapeutic approaches for some important malignant diseases by virtue of their targeting， high efficiency and low toxicity. However， along with a large number of nanomedicines entering preclinical or clinical studies， the concern for their biosafety is also increasing. Until now， no consensus has been reached on the evaluation of the efficacy and safety of nanomaterials at home and abroad， and the development of nanomedicine still lacks scientific and systematic standards. On this basis， the "EU Horizon 2020- SAFE-N-MEDTECH" project attempts to cooperate relevant personnel from research institutes and industries in the field of nanomedicine from Europe， South America and China to initiate the research on the evaluation of the efficacy and safety of innovative nanomaterials，so as to establish an open testing platform of nanotechnology-enabled medical technologies for health, thereby promoting the globalization of the nanotechnology industry. The research interest of our team focused on the development of innovative nanomedicines for tumor and bone-related diseases under the frame of "EU Horizon 2020- SAFE-N-MEDTECH" project. In this review, we briefly describes the advantages and characteristics of nanomedicines, as well as the strategies and ideas of establishing nanomedicines according to the characteristics of diseases, hoping to provide some expertise and help to practitioners in the field of nanomedicine.

Key words: Nanomedicine, Nanotechnology, Malignancy, Rheumatoid arthritis, The EU Horizon 2020 Project

中图分类号:

王祉琪, 黄元政, 朱丹丹, 刘潇璇, 梁兴杰, . 纳米药物研发的实践与思考[J]. 中国医药导刊, 2022, 24(4): 305-313.

WANG Zhiqi , HUANG Yuanzheng, ZHU Dandan, LIU Xiaoxuan, LIANG Xingjie , . Exploration and Considerations on the Development of Nanomedicine[J]. CHINESE JOURNAL OF MEDICINAL GUIDE, 2022, 24(4): 305-313.

参考文献

[1] Kagan CR， Fernandez LE， Gogotsi Y， et al. Nano day:celebrating the next decade of nanoscience and nanotechnology[J]. ACS Nano，2016， 10(10)：9093-9103.
     [2]Matsiko A.Nanomedicine：design and conquer[J].Nat Rev Mater，2017， 2:17034.
     [3]Zhang C， Yan L， Wang X， et al.Progress，challenges， and future of nanomedicine[J]. Nano Today，2020，35:101008.
     [4]Muggia FM.Doxil in breast cancer[J]. J Clin Oncol，1998，16(2)：811-812.
     [5]Mast MP， Modh H， Champanhac C， et al.Nanomedicine at the crossroads - a quick guide for IVIVC[J]. Adv Drug Deliv Rev，2021，179：113829.
     [6]Sun Q， Zhou Z， Qiu N， et al.Rational design of cancer nanomedicine：nanoproperty integration and synchronization[J]. Adv Mater，2017， 29(14)：1606628.
     [7]Da SA， Damian B， Adam B， et al.To PEGylate or not to PEGylate：immunological properties of nanomedicine′s most popular component， polyethylene glycol and its alternatives[J]. Adv Drug Deliv Rev， 2022，180：114079.
     [8]Wang HX， Zuo ZQ， Du JZ， et al. Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines[J].Nano Today，2016，11(2)：133-144.
     [9]Battistella C， Liang Y， Gianneschi N C. Innovations in disease state responsive soft materials for targeting extracellular stimuli associated with cancer，cardiovascular disease， diabetes， and beyond[J]. Adv Mater，2021，33(46)：e2007504.
     [10]Cao W， Chen HD， Yu YW， et al. Changing profiles of cancer burden worldwide and in China：a secondary analysis of the global cancer statistics 2020[J].Chin Med J(Engl)，2021，134(7)：783-791.
     [11]Deborah P，Adam CPr，SorgerPK. Independent drug action in combination therapy：implications for precision oncology[J]. Cancer Discov，2022， 12(3)：606-624.
     [12]Spranger S.Tumor heterogeneity and tumor immunity：a chicken-and-egg problem[J]. Trends Immunol，2016， 37(6)：349-351.
     [13]Cai Y， Chen X， Si J， et al..All-in-one nanomedicine:multifunctional single-component nanoparticles for cancer theranostics[J]. Small，2021，17(52)：e2103072.
     [14]Sabrina D，Vladimir D c＇，Loretta L，et al.Improvement of conventional anti-cancer drugs as new tools against multidrug resistant tumors[J].Drug Resist Updat，2020，50：100682.
     [15]Timothy CJ，Kogularamanan S，Lippard SJ.The next generation of platinum drugs：targeted Pt(II) agents， nanoparticle delivery， and Pt(IV) prodrugs[J]. Chem Rev， 2016，116(5)：3436-3486.
     [16]Holzer AK， Manorek GH， Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin， carboplatin， and oxaliplatin[J].Mol Pharmacol， 2006，70(4)：1390-1394.
     [17]Ling X， Chen X，Riddell IA， et al. Glutathione-scavenging poly(disulfide amide) nanoparticles for the effective delivery of Pt(IV) prodrugs and reversal of cisplatin resistance[J]. Nano Lett，2018，18(7)：4618-4625.
     [18]Sancar A.Mechanisms of DNA repair by photolyase and excision nuclease(nobel lecture)[J]. Angew Chem Int Ed Engl，2016，55(30)：8502-8527.
     [19]Cao Q， Zhou DJ，Zheng YP，et al.CAIXplatins:highly potent platinum(IV) prodrugs selective against carbonic anhydrase IX for the treatment of hypoxic tumors[J]. Angew Chem Int Ed Engl，2020，59(42)：18556-18562.
     [20]Slamon D，Yeon CH，Pienkowski T，et al.Survival analysis from two open-label non-randomized phase II trials of trastuzumab(H) combined with docetaxel(T) and platinums(C， cisplatin or carboplatin)(TCH) in women with HER2+ advanced breast cancer(ABC)[J]. J Clin Oncol，2004，22(14)：642-642.
     [21]Cheng HJ， Wu TH， Chien CT， et al.Corrosion-activated chemotherapeutic function of nanoparticulate platinum as a cisplatin resistance-overcoming prodrug with limited autophagy induction[J]. Small，2016，12(44)：6124-6133.
     [22]Zeng XL， Wang YF，Han JX，et al.Fighting against drug-resistant tumors using a dual-responsive Pt(IV)/Ru(II) bimetallic polymer[J]. Adv Mater，2020，32(43)：e2004766.
     [23]I Galani IE， Eynav K， Evangelos A. Human and translational immunology in the third millennium：progress，challenges and opportunities[J].Nat Immunol，2019，20(12)：1568-1573.
     [24]Le QV， Suh J， Choi JJ， et al. In Situ nanoadjuvant-assembled tumor vaccine for preventing long-term recurrence[J]. ACS Nano，2019，13(7):7442-7462.
     [25]Wang YC，Gong NQ，Ma C，et al.An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ cancer vaccination[J].Nat Commun，2021，12(1)：4964.
     [26]Hinman SS，Ruiz CJ，Cao Y，et al.Mix and match：coassembly of amphiphilic dendrimers and phospholipids creates robust， modular， and controllable interfaces[J]. ACS Appl Mater Interfaces， 2017， 9(1)：1029-1035.
     [27]Chen Y，Ambade AV，Vutukuri DR， et al. Self-assembly of facially amphiphilic dendrimers on surfaces[J]. J Am Chem Soc， 2006， 128(46)：14760-14761.
     [28]Ding L，Lyu Z，Tintaru A，et al.A self-assembling amphiphilic dendrimer nanotracer for SPECT imaging[J].Chem Commun(Camb)，2019，56(2)：301-304.
     [29]Wei T，Chen C，Liu J，et al.Anticancer drug nanomicelles formed by self-assembling amphiphilic dendrimer to combat cancer drug resistance[J].Proc Natl Acad Sci USA，2015，112(10)：2978-2983.
     [30]Chang DW，Sohn GJ，Dai L，et al. Reversible adsorption of conjugated amphiphilic dendrimers onto reduced graphene oxide(rGO) for fluorescence sensing[J]. Soft Matter，2011，7(18):8352-8357.
     [31]Zhu DD， Zhang HL， Huang YZ，et al.A self-assembling amphiphilic peptide dendrimer-based drug delivery system for cancer therapy[J]. Pharmaceutics，2021，13(7)：1092.
     [32]Li ZG.A new look at rheumatology in China-opportunities and challenges[J].Nat Rev Rheumatol，2015，11(5)：313-317.
     [33]Smolen JS，Aletaha D，McInnes IB. Rheumatoid arthritis[J]. The Lancet，2016，388(10055)：2023-2038.
     [34]Yang M，Feng X，Ding J，et al.Nanotherapeutics relieve rheumatoid arthritis[J].J Control Release，2017，252:108-124.
     [35]Kulkarni JA，Witzigmann D，Thomson SB，et al.The current landscape of nucleic acid therapeutics[J].Nat Nanotechnol，2021，16(6)：630-643.
     [36]Gupta A，Andresen JL，Manan RS，et al.Nucleic acid delivery for therapeutic applications[J]. Adv Drug Deliv Rev， 2021，178：113834.
     [37]Chen Y，Hong T，Wang S，et al.Epigenetic modification of nucleic acids：from basic studies to medical applications[J].Chem Soc Rev，2017，46(10)：2844-2872.
     [38]van Haasteren J，Li J，Scheideler OJ，et al.The delivery challenge：fulfilling the promise of therapeutic genome editing[J].Nat Biotechnol，2020，38(7)：845-855.
     [39]Fattal E，Fay F.Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases[J]. Adv Drug Deliv Rev，2021，175：113809.
     [40]Samaridou E，Heyes J，Lutwyche P. Lipid nanoparticles for nucleic acid delivery：Current perspectives[J]. Adv Drug Deliv Rev，2020，154-155：37-63.
     [41]Kumar R，Santa CF，Bockman MR，et al.Polymeric delivery of therapeutic nucleic acids[J]. Chem Rev，2021，121(18)：11527-11652.
     [42]Chen L，Hong W，Ren W，et al.Recent progress in targeted delivery vectors based on biomimetic nanoparticles[J]. Signal Transduct Target Ther， 2021， 6(1)：225.
     [43]Ledford H. Gene-silencing technology gets first drug approval after 20-year wait[J]. Nature， 2018，560(7718)：291-292.
     [44]Hoy SM. Patisiran：first global approval[J]. Drugs，2018， 78(15)：1625-1631.
     [45]Fang E，Liu X，Li M，et al.Advances in COVID-19 mRNA vaccine development[J]. Signal Transduct Target Ther，2022，7(1)：94.
     [46]Tomalia DA，Frechet JMJ. Discovery of dendrimers and dendritic polymers：a brief historical perspective[J].J Polym Sci Pol Chem，2002，40(16)：2719-2728.
     [47]Kheraldine H，Rachid O，Habib AM，et al. Emerging innate biological properties of nano-drug delivery systems：a focus on PAMAM dendrimers and their clinical potential[J]. Adv Drug Deliver Reviews， 2021， 178:113908.
     [48]Kannan RM，Nance E，Kannan S，et al.Emerging concepts in dendrimer-based nanomedicine：from design principles to clinical applications[J].J Intern Med， 2014，276(6)：579-617.
     [49]Dong Y，Yu T，Ding L，et al.A dual targeting dendrimer-mediated siRNA delivery system for effective gene silencing in cancer therapy[J].J Am Chem Soc，2018，140(47)：16264-16274.
     [50]Liu XX，Wang Y，Chen C，et al.A fluorinated bola-amphiphilic dendrimer for on-demand delivery of siRNA， via specific response to reactive oxygen species[J]. Adv Funct Mater，2016，26(47)：8594-8603.
     [51]Zhang D，Atochina-Vasserman EN，Maurya DS，et al.One-component multifunctional sequence-defined ionizable amphiphilic janus dendrimer delivery systems for mRNA[J].J Am Chem Soc，2021，143(31):12315-12327.
     [52]Dong Y，Chen Y，Zhu D，et al.Self-assembly of amphiphilic phospholipid peptide dendrimer-based nanovectors for effective delivery of siRNA therapeutics in prostate cancer therapy[J]. J Control Release，2020，322：416-425.
     [53]Chen JX，Ellert-Miklaszewska A，Garofalo S，et al.Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells[J]. Nat Protoc，2021，16(1)：327-351.
     [54]Ma C，Zhu D，Chen Y， et al.Amphiphilic peptide dendrimer-based nanovehicles for safe and effective siRNA delivery[J]. Biophysics Reports，2020，6(6)：278-289.
     [55]Fredman G.DELineating resolution of inflammation[J]. Nat Immunol，2019，20(1)：2-3.
     [56]Yuan F，Quan LD，Cui L，et al.Development of macromolecular prodrug for rheumatoid arthritis[J]. Adv Drug Deliv Rev，2012，64(12):1205-1219.
     [57]Firestein GS，McInnes IB. Immunopathogenesis of rheumatoid arthritis[J].Immunity，2017，46(2):183-196.
     [58]刘潇璇，陈朋，朱丹丹，等.两亲性树形分子、合成及其作为药物递送系统的应用：中国， CN113214171A[P].2020.

快速检索引用检索图表检索高级检索